Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Background. In 1999, meningococcal serogroup C conjugate (MCC) vaccines were introduced in the United Kingdom for those under 19 years of age. The impact of this intervention on asymptomatic carriage of meningococci was investigated to establish whether serogroup replacement or protection by herd immunity occurred. Methods. Multicenter surveys of carriage were conducted during vaccine introduction and on 2 successive years, resulting in a total of 48,309 samples, from which 8599 meningococci were isolated and characterized by genotyping and phenotyping. Results. A reduction in serogroup C carriage (rate ratio, 0.19) was observed that lasted at least 2 years with no evidence of serogroup replacement. Vaccine efficacy against carriage was 75%, and vaccination had a disproportionate impact on the carriage of sequence type (ST)-11 complex serogroup C meningococci that (rate ratio, 0.06); these meningococci also exhibited high rates of capsule expression. Conclusions. The impact of vaccination with MCC vaccine on the prevalence of carriage of group C meningococci was consistent with herd immunity. The high impact on the carriage of ST-11 complex serogroup C could be attributed to high levels of capsule expression. High vaccine efficacy against disease in young children, who were not protected long-term by the schedule initially used, is attributed to the high vaccine efficacy against carriage in older age groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The reduction in carriage lasted for at least 2 years after vaccine introduction, with no evidence of serogroup replacement (199).”
From Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The staden sequence analysis package
Staden, R. (1996) · Molecular Biotechnology · doi:10.1007/bf02900361 · Cited by 1,263
Multilocus Sequence Typing of Bacteria
Maiden, M. C. J. (2006) · Annual Review of Microbiology · doi:10.1146/annurev.micro.59.030804.121325 · Cited by 915
Self-citationEffectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16725-1 · Cited by 571 · cited 1×
“This was fortuitous given that the infant schedule used for MCC vaccines in the United Kingdom at the time of vaccine introduction did not confer long term protection [27].”
BackgroundSelf-citationSequence type analysis and recombinational tests (START)
Jolley, K. A., Feil, E. J., Chan, M.-S., & Maiden, M. C. J. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.12.1230 · Cited by 512
Self-citationmlstdbNet – distributed multi-locus sequence typing (MLST) databases
Jolley, K. A., Chan, M.-S., & Maiden, M. C. (2004) · BMC Bioinformatics · doi:10.1186/1471-2105-5-86 · Cited by 501
Self-citationMiller, E., Salisbury, D., & Ramsay, M. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 482
Dagan, R., Melamed, R., Muallem, M., Piglansky, L., Greenberg, D., Abramson, O., Mendelman, P. M., Bohidar, N., & Yagupsky, P. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.6.1271 · Cited by 477
Immunologic Response of Man to Group B Meningococcal Polysaccharide Vaccines
Wyle, F. A., Artenstein, M. S., Brandt, B. L., Tramont, E. C., Kasper, D. L., Altieri, P. L., Berman, S. L., & Lowenthal, J. P. (1972) · Journal of Infectious Diseases · doi:10.1093/infdis/126.5.514 · Cited by 446
The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica
Cartwright, K. A. V., Stuart, J. M., Jones, D. M., & Noah, N. D. (1987) · Epidemiology and Infection · doi:10.1017/s0950268800066449 · Cited by 421
Self-citationMaiden, M. C., & Stuart, J. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08679-8 · Cited by 418 · cited 4×
“bacteria [13], which, although rarely isolated from carriers, are”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 1
- 12. Jelfs J, Munro R, Ashton F, Rawlinson W, Caugant DA. Global study of variation in a new variant of the ET-37 complex of Neisseria meningitidis. In: Program and abstracts of the 11th International Pathogenic Neisseria Conference. Nice, France: Editions E.D.K., 1998 :5.
Cited by
Items 301–400 of 488
Greenwood, B. M., Aseffa, A., Caugant, D. A., Diallo, K., Kristiansen, P. A., Maiden, M. C. J., Stuart, J. M., & Trotter, C. L. (2018) · Tropical Medicine & International Health · doi:10.1111/tmi.13185 · Cited by 11
Self-citationThe Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment
Maiden, M. C. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03151 · Cited by 11
Self-citationSpinsanti, M., Brignoli, T., Bodini, M., Fontana, L. E., Chiara, M. D., Biolchi, A., Muzzi, A., Scarlato, V., & Delany, I. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009461 · Cited by 11
Challenges for development of meningococcal vaccines in infants and children
Deasy, A. M., & Read, R. C. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.3 · Cited by 11
Commencement of the Meningococcal Vaccination for the Republic of Korea Army
Lee, S. (2013) · Infection and Chemotherapy · doi:10.3947/ic.2013.45.1.113 · Cited by 11
Vesikari, T., Forstén, A., Desole, M. G., Ferrera, G., Caubet, M., Mesaros, N. E., & Boutriau, D. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31827e22e3 · Cited by 11
Vaccines for Prevention of Group B Meningococcal Disease
Harrison, L. H. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.09.007 · Cited by 11
Hogea, C. S., Effelterre, T. P. V., & Cassidy, A. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-291 · Cited by 11
Good News and Bad News — 4CMenB Vaccine for Group B Neisseria meningitidis
Harrison, L. H., & Stephens, D. S. (2020) · New England Journal of Medicine · doi:10.1056/nejme1916440 · Cited by 11
Miellet, W. R., Pluister, G. N., Sikking, M., Tappel, M., Karczewski, J., Visser, L. J., Bosch, T., Trzciński, K., & Mariman, R. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.078 · Cited by 10
Díez‐Domingo, J., Simkó, R., Icardi, G., Chong, C. P., Zocchetti, C., Syrkina, O., Bchir, S., & Bertrand-Gerentes, I. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01009-x · Cited by 10
Mattheus, W., Hanquet, G., Collard, J., Vanhoof, R., & Bertrand, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139615 · Cited by 10
Vianzon, V. V., Illek, B., & Moe, G. R. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00188-17 · Cited by 10
Hogea, C. S., Effelterre, T. P. V., & Vyse, A. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1080400 · Cited by 10
Marshall, H. S., McMillan, M., Koehler, A. P., Lawrence, A. J., MacLennan, J. M., Maiden, M. C. J., Ramsay, M. E., Ladhani, S. N., Trotter, C. L., Borrow, R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027233 · Cited by 10
Self-citationMarshall, H. S., Baber, J., Richmond, P., Nissen, M. D., Shakib, S., Kreiswirth, B. N., Zito, E. T., Severs, J. M., Eiden, J., Gruber, W. C., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.09.018 · Cited by 10
Annual report of the Australian Meningococcal Surveillance Programme, 2009
Australian Meningococcal Surveillance Programme, & Lahra, M. M. (2010) · Communicable Diseases Intelligence · doi:10.33321/cdi.2010.34.29 · Cited by 10
Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria
Durando, P., Faust, S. N., & Torres, A. (2015) · Journal of Immunology Research · doi:10.1155/2015/934504 · Cited by 10
Meningococcal C booster not recommended by evidence
Thomas, H. L., Andrews, N. J., Trotter, C. L., Ramsay, M. E., & Miller, E. (2008) · BMJ · doi:10.1136/bmj.a1139 · Cited by 10
Self-citationCooper, L., Boukary, R. M., Aseffa, A., Mihret, W., Collard, J., Daugla, D. M., Hodgson, A., Sokhna, C., Omotara, B. A., Sow, S. O., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182575 · Cited by 9
Self-citationMcMillan, M., Bednarz, J., Leong, L. E. X., Lawrence, A. J., & Marshall, H. S. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003660 · Cited by 9
Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany
Gruhn, S., Batram, M., Wick, M., Langevin, E., Scholz, S. M., Greiner, W., & Damm, O. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00958-7 · Cited by 9
Martinón‐Torres, F., Serra, L., & Sáfadi, M. A. P. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1745070 · Cited by 9
Meningococcal disease and vaccination in college students
DeRoo, S. S., Torres, R. G., & Fu, L. Y. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1973881 · Cited by 9
Vicente, D. A., Esnal, O., de Goicoechea, M. J. L., Cisterna, R., & Pérez‐Trallero, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008501 · Cited by 9
Findlow, H., Borrow, R., Hardelid, P., Newton, E., Frankland, S., Naylor, S., Miller, E., Kaczmarski, E., & Read, R. C. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00503-10 · Cited by 9
Self-citationMorales, D., Cenoz, M. G., Moreno‐Galarraga, L., Bernaola, E., Barricarte, A., & Castilla, J. (2016) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.11.020 · Cited by 8
Prevention of serogroup B meningococcal disease
Stephens, D. S. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61934-x · Cited by 8
Carriage and transmission of Neisseria meningitidis
Trotter, C. L., & Maiden, M. C. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-28119-3_2 · Cited by 8
Self-citationΚεσανόπουλος, Κ., Bratcher, H. B., Hong, E., Xirogianni, A., Papandreou, A., Taha, M., Maiden, M. C. J., & Tzanakaki, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209919 · Cited by 8
Self-citationMulhall, R., Bennett, D. E., Bratcher, H. B., Jolley, K. A., Bray, J. E., O’Lorcain, P. P., Cotter, S. M., Maiden, M. C. J., & Cunney, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216771 · Cited by 8
Self-citationMeningococcal and pneumococcal carriage in Hajj pilgrims: findings of a randomized controlled trial
Badahdah, A.-M. M., Bakarman, M. A., Khatami, A., Tashani, M., Barasheed, O., Alfelali, M., Azeem, M. I., Bokhary, H., Soltan, O., Lahra, M. M., et al. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa032 · Cited by 8
Fukushima, S., Kikuchi, H., Miyazu, M., Hamada, A., Ouchi, K., Takagi, H., Mihara, H., Sasaki, T., Oka, H., Bosch-Castells, V., et al. (2018) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2017.277 · Cited by 8
Gbesemete, D. F., Laver, J. R., de Graaf, H., Ibrahim, M., Vaughan, A., Faust, S. N., GORRINGE, A. R., & Read, R. C. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026544 · Cited by 8
Annual report of the Australian Meningococcal Surveillance Programme, 2007 – Amended
Australian Meningococcal Surveillance Programme, & TAPSALL, J. W. (2009) · Communicable Diseases Intelligence · doi:10.33321/cdi.2009.33.1 · Cited by 8
European efforts to harmonize typing of meningococci
Vogel, U. F. (2011) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2011.09.001 · Cited by 8
Katz, S. E., Townsend‐Payne, K., Louth, J. C., Lee‐Jones, L., Trotter, C. L., Dano, I. D., & Borrow, R. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.013 · Cited by 7
A vaccine to prevent epidemic meningitis in Africa
Greenwood, B. M., & Stuart, J. M. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70182-2 · Cited by 7
Self-citationAdvances in meningococcal vaccines
Pizza, M., DeTora, L. M., & Wassil, J. (2012) · Clinical Practice · doi:10.2217/cpr.11.128 · Cited by 7
Potential impact of the 4CMenB vaccine on oropharyngeal carriage of Neisseria meningitidis
Abad, R., Medina, V., Fariñas, M. C., Martínez-Martínez, L., Bambini, S., Dari, A., Medini, D., Pizza, M., & Vázquez, J. A. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.09.021 · Cited by 7
Menichetti, F., Fortunato, S., Ricci, A., Salani, F., Ripoli, A., Tascini, C., Fusco, F. M., Mencarini, J., Bartoloni, A., & Pietro, M. D. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.050 · Cited by 7
Australian Meningococcal Surveillance Programme annual report, 2010
Australian Meningococcal Surveillance Programme, & Lahra, M. M. (2011) · Communicable Diseases Intelligence · doi:10.33321/cdi.2011.35.20 · Cited by 7
Holmes, J. C., Green, L. R., Oldfield, N. J., Turner, D. P. J., & Bayliss, C. D. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.579411 · Cited by 7
A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study
Hanquet, G., Christensen, H., Agnew, E., Trotter, C. L., Robays, J., Dubois, C., Devriese, S., de Sande, S. V., & Thiry, N. (2014) · doi:10.57598/r231c · Cited by 7
Annual report of the Australian Meningococcal Surveillance Programme, 2008
Australian Meningococcal Surveillance Programme, & TAPSALL, J. W. (2009) · Communicable Diseases Intelligence · doi:10.33321/cdi.2009.33.28 · Cited by 7
Sv, S., Захаренко, С. М., Lobzin, Y. V., Zhdanov, K. V., Martens, E. A., Валерьевич, Г. В., Mokhov, A. S., Волкова, М. О., Kalinogorskaya, O. S., Gelezova, L., et al. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.12.012 · Cited by 7
Microbiología y salud pública: nuevos retos en vigilancia y control de la enfermedad meningocócica
Abad, R., & Vázquez, J. A. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.01.002 · Cited by 6
Vaccins anti-méningococciques: Des vaccins polysaccharidiques aux vaccins conjugués
Cohen, R., & Lévy, C. (2012) · Archives de Pédiatrie · doi:10.1016/s0929-693x(12)71275-7 · Cited by 6
Hovmand, N., Lundbo, L. F., Kronborg, G., Voss, S. S., Sandholdt, H., Hoffmann, S., Valentiner‐Branth, P., & Benfield, T. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.086 · Cited by 6
Drew, R. J., Bennett, D. E., O’Donnell, S., Mulhall, R., & Cunney, R. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940651 · Cited by 6
Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines
McNamara, L. A., Pollard, A. J., & Harrison, L. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00039-6 · Cited by 6
Jackson, M. L., Diallo, A. O., Médah, I., Bicaba, B. W., Yaméogo, I., Koussoubé, D., Ouédraogo, R., Sangaré, L., & Mbaeyi, S. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206117 · Cited by 6
Currie, E. G., & Gray‐Owen, S. D. (2021) · Pathogens · doi:10.3390/pathogens10070906 · Cited by 6
Australian Meningococcal Surveillance Programme annual report, 2012
Lahra, M. M., & Enriquez, R. P. (2013) · Communicable Diseases Intelligence · doi:10.33321/cdi.2013.37.34 · Cited by 6
Shibl, A. M., Tufenkeji, H., Khalil, M., & Memish, Z. A. (2012) · Journal of Epidemiology and Global Health · doi:10.1016/j.jegh.2012.02.002 · Cited by 6
Pace, D. (2010) · Future Microbiology · doi:10.2217/fmb.10.137 · Cited by 6
Stoof, S. P., Buisman, A., van Rooijen, D. M., Boonacker, R., van der Klis, F. R. M., Sanders, E. A. M., & Berbers, G. A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138665 · Cited by 6
Findlow, H., & Borrow, R. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0169-1 · Cited by 6
Rashid, H., & Khatami, A. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-1597-7 · Cited by 6
Prevention of Meningococcal Infections in the First 2 Years of Life
Woods, C. R. (2013) · Pediatric Annals · doi:10.3928/00904481-20130723-11 · Cited by 6
Bratcher, H. B., Rodrigues, C. M. C., Finn, A. H. R., Wootton, M., Cameron, J. C., Smith, A. J., Heath, P. T., Ladhani, S. N., Snape, M. D., Pollard, A. J., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15362.1 · Cited by 6
Self-citationEditorial Commentary: The Endgame for Serogroup A Meningococcal Disease in Africa?
Maiden, M. C. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis896 · Cited by 6
Self-citationClimate influences on infectious diseases in Nigeria, West Africa
Abdussalam, A. F. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 6
Whelan, J., Marshall, H. S., & Sullivan, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254330 · Cited by 5
Hygiene, J. O. P. M. A. (2021) · PubMed Central · doi:10.15167/2421-4248/jpmh2021.62.1s1 · Cited by 5
Kim, Y. R., Hyun, H., Kim, E., Choi, Y. H., Yoo, J. S., Lee, Y., Oh, H. S., & Heo, J. Y. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107150 · Cited by 5
Adams, L., Karachaliou, A., Hadley, L., Ramsay, M. E., Campbell, H., & Trotter, C. L. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126240 · Cited by 5
Meningococcal Vaccination in the United States: Past, Present, And Future
Schillie, S. F., & McNamara, L. A. (2025) · Pediatric Drugs · doi:10.1007/s40272-024-00666-2 · Cited by 5
Doença meningocócica invasiva nas capitais da Região Sul do Brasil: características e tendências
Masuda, E. T. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2018.tde-21062018-105510 · Cited by 5
Evaluating the Impact of Meningococcal Vaccines With Synthetic Controls
Prunas, O., Weinberger, D. M., Medini, D., Tizzoni, M., & Argante, L. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab266 · Cited by 4
Nathanson, D. (2016) · American Journal of Law & Medicine · doi:10.1177/0098858816658282 · Cited by 4
Hospitalizations related to meningococcal infection in Spain from 1997 to 2018
Walter, S., Gil-Prieto, R., Gil-Conesa, M., Rodríguez‐Caravaca, G., Román, J. S., & de Miguel, Á. G. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06916-9 · Cited by 4
Findlow, H., & Borrow, R. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1019189 · Cited by 4
Impfstoffe gegen Meningokokken für das Kindesalter
Tenenbaum, T., Hellenbrand, W., & Schroten, H. (2019) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-018-0635-7 · Cited by 4
Travelers' Protection Against Meningococcal Disease: A New Vaccine Option
BLACK, S. B. (2010) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.2010.00450.x · Cited by 4
Quadrivalent meningococcal conjugated vaccine: A routine or selective vaccine in Europe?
Aumatell, C. M., Borrow, R., & Zuckerman, J. N. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.04.008 · Cited by 4
Itria, A. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2011.tde-12012012-092948 · Cited by 4
Unterschiedliche Impfschemata in Europa: Führen alle Wege nach Rom?
Wiedermann, U. (2009) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-009-1974-1 · Cited by 3
Doubinsky, A., Deyi, V. Y. M., Mattheus, W., Delforge, M., Libois, A., Dauby, N., & Nasreddine, R. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-05031-2 · Cited by 3
Vaccination Against Meningococcal Disease in Children—A European Perspective
Næss, L. M., & Watle, S. V. (2025) · Acta Paediatrica · doi:10.1111/apa.70224 · Cited by 3
Rossotti, R., Merli, M., Cantone, M., Moioli, M. C., Motta, D., Orcese, C., Pazzi, A., Travi, G., Vigo, B., & Puoti, M. (2019) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2019.1642512 · Cited by 3
Where next? The emergence of hypervirulent W meningococcus in the Netherlands
Broad, J., & Snape, M. D. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30163-9 · Cited by 3
Neveu, D., Moore, T. M., Zambrano, B., Chen, A., Kürzinger, M., Marcelon, L., & Dhingra, M. S. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00864-4 · Cited by 3
Marshall, H. S., & Maiden, M. C. J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1253 · Cited by 3
Self-citationGonçalves, P., Sáez-López, E., Carneiro, S., & Simões, M. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250103 · Cited by 3
Koski, S., Martinón‐Torres, F., Rämet, M., Zolotas, L., Newton, R., Maansson, R., Cutler, M. W., Peyrani, P., Findlow, J., Balmer, P., et al. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01098-8 · Cited by 2
Current Trends in Meningococcal Infection and Possibilities of Vaccine Prevention
Koroleva, I. S., Churilova, N. S., Davydenko, M. A., Pivneva, M. V., & Миронов, К. О. (2025) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2025-24-5-24-34 · Cited by 2
Gbesemete, D. F., Haidara, F. C., Laver, J. R., Ibrahim, M., MacLennan, J. M., Dale, A. P., GORRINGE, A. R., Traore, Y., Diallo, F., Badji, H., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf809 · Cited by 2
Self-citationAustralian Meningococcal Surveillance Programme Annual Report, 2024
Lahra, M. M., Hurley, S. M., George, C., van Hal, S. J., & Hogan, T. R. (2025) · Communicable Diseases Intelligence · doi:10.33321/cdi.2025.49.057 · Cited by 2
Abad, R., Martinón‐Torres, F., Santolaya, M. E., Banzhoff, A., González-Inchausti, C., Graña, M. G., & Vázquez, J. A. (2019) · PubMed Central · Cited by 2
Current developments and trends in childhood immunization
Thors, V. S., Marlow, R. D., & Finn, A. H. R. (2013) · Paediatrics and Child Health · doi:10.1016/j.paed.2012.11.015 · Cited by 2
Cotrim, J., Carvalho, J., Sá, A., Pereira, A., Cândido, C., & Dias, F. (2011) · Nascer e crescer · Cited by 2
de Voer, R. M., van der Klis, F. R. M., Niers, L. E. M., Rijkers, G. T., & Berbers, G. A. M. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00274-09 · Cited by 2
Infectious Syndromes in the Pediatric Intensive Care Unit
Dhanani, S., & Cox, P. N. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-07307-3.10096-5 · Cited by 2
Pérez–Breva, L., Abad, R., Martínez‐Beneito, M. A., Puig‐Barberà, J., Alemán-Sánchez, S., Talamante, N. M., Sastre-Cantón, M., Vázquez, J. A., & Díez‐Domingo, J. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.022 · Cited by 2
Formulation Development of Glycoconjugate Vaccines for Low- and Middle-Income Countries
Khandke, L., Welsch, J. A., & Alderson, M. R. (2018) · ACS symposium series · doi:10.1021/bk-2018-1290.ch009 · Cited by 2
Practical Use of Meningococcal Vaccines—Whom and When to Vaccinate
Harrison, L. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00007-0 · Cited by 2
Facchetti, A., Wheeler, J. X., Vipond, C., Whiting, G. C., Lavender, H., Feavers, I. M., Maiden, M. C. J., & Maharjan, S. (2021) · Access Microbiology · doi:10.1099/acmi.0.000255 · Cited by 2
Self-citationMarquez, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00088-1 · Cited by 2
Investigation of the potential of PorA and FetA as meningococcal vaccine components
Sanders, H. (2012) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-mqr5pr2py · Cited by 2
Metadata
- Authors
- Maiden, M. C. J., Ibarz-Pavón, A. B., Urwin, R., Gray, S. J., Andrews, N. J., Clarke, S. C., Walker, A. M., Evans, M. R., Kroll, J. S., Neal, K. R., Ala'Aldeen, D. A. A., Crook, D. W., Cann, K., Harrison, S., Cunningham, R., Baxter, D., Kaczmarski, E., MacLennan, J., Cameron, J. C., & Stuart, J. M.
- Affiliations
- John Radcliffe Hospital (GB)
- Health Protection Agency (GB)
- Health Protection Agency Centre for Infections, London
- University of Southampton (GB)
- Bangor University (GB)
- National Public Health Service for Wales, Unit 1, Parc Nantgarw, Cardiff
- Imperial College London (GB)
- University of Nottingham (GB)
- Division of Microbiology, School of Molecular Medical Sciences, Institute of Infection Immunity and Inflammation University of Nottingham
- South West Peninsula Health Protection Unit, Lescaze Offices, Dartington, Devon
- Derriford Hospital (GB)
- University of Manchester (GB)
- Manchester Royal Infirmary (GB)
- Health Protection Scotland (GB)
- Corresponding author
- Maiden, Martin C J
- ORCID
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-01
- Volume
- 197
- Issue
- 5
- Pages
- 737-743
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC6767871
- OpenAlex
- W2171028861
- Cited by
- 442
- References
- 41
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 9 · 2023: 16 · 2022: 10 · 2021: 21 · 2020: 18 · 2019: 21 · 2018: 29 · 2017: 32 · 2016: 24 · 2015: 40 · 2014: 22 · 2013: 28 · 2012: 45
- FWCI
- 35.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Funders
- Wellcome Trust
- Scottish Executive Health Department
- Meningitis Trust
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Keywords
- meningococcal serogroup C, conjugate vaccines, asymptomatic carriage, herd immunity, serogroup replacement, capsule expression, vaccine efficacy, young children, United Kingdom
- MeSH terms
- Adolescent, Adult, Carrier State, Cross-Sectional Studies, United Kingdom, Humans, Meningococcal Infections, Neisseria meningitidis, Serotyping, Meningococcal Vaccines, Immunity, Herd, Mass Vaccination, Neisseria meningitidis, Serogroup C
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.